England’s NICE Leads Global Effort On Surrogate Endpoints For Cost-Effectiveness

 
• By Eliza Slawther

Health technology assessment bodies in England, the US, Canada, Australia, the Netherlands and Colombia have joined forces to produce guidance for drug developers on using surrogate endpoints for cost-effectiveness analyses.

(Shutterstock)

More from Health Technology Assessment

More from R&D